Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Chang, Mark
Song, Alexander
Deyo, Logan James
Stamos, Daniel
Bloomer, Chance H.
Khoury, Lara M.
Porosnicu, Mercedes
机构：
[1] Atrium Hlth Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[2] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6062
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma
    Hui, Rongrong
    Liu, Xiulan
    Fan, Zongyu
    Ji, Honghai
    Wei, Dongliang
    Ren, Guoxin
    [J]. JOURNAL OF CANCER, 2024, 15 (06): : 1668 - 1674
  • [2] Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma
    Rabjerg, Helene Knap
    Eriksen, Jesper Grau
    Soby, Sebastian
    [J]. ORAL ONCOLOGY, 2024, 158
  • [3] FACTORS EVALUATED AS PREDICTORS OF EXCEPTIONAL RESPONSE TO PD-1 INHIBITORS IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CANCER
    Song, Alexander
    Ng, Ron
    Heller, John
    Petro, Robin
    D'Agostino, Ralph
    Lycan, Thomas
    Porosnicu, Mercedes
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A151 - A151
  • [4] Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Yin, Gaofei
    Guo, Wei
    Duan, Hanyuan
    Huang, Zhigang
    [J]. CLINICAL OTOLARYNGOLOGY, 2021, 46 (05) : 1013 - 1020
  • [5] Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma
    Kumai, Takumi
    Komatsuda, Hiroki
    Minami, Yoshinori
    Harabuchi, Yasuaki
    [J]. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 2020, 82 (06): : 343 - 350
  • [6] American Head and Neck Society position statement on the use of PD-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma
    Schmalbach, Cecelia E.
    Ow, Thomas J.
    Choi, Karen Y.
    O'Leary, Miriam
    Lin, Alice
    Hughley, Brian B.
    Emerick, Kevin S.
    Moore, Brian
    Lee, Nancy Y.
    Zandberg, Dan P.
    Wang, Steven J.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (01): : 32 - 41
  • [7] The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck
    Zandberg, Dan P.
    Strome, Scott E.
    [J]. ORAL ONCOLOGY, 2014, 50 (07) : 627 - 632
  • [8] Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma
    Van Allen, Eliezer M.
    Lui, Vivian W. Y.
    Egloff, Ann Marie
    Goetz, Eva M.
    Li, Hua
    Johnson, Jonas T.
    Duvvuri, Umamaheswar
    Bauman, Julie E.
    Stransky, Nicolas
    Zeng, Yan
    Gilbert, Breean R.
    Pendleton, Kelsey P.
    Wang, Lin
    Chiosea, Simion
    Sougnez, Carrie
    Wagle, Nikhil
    Zhang, Fan
    Du, Yu
    Close, David
    Johnston, Paul A.
    McKenna, Aaron
    Carter, Scott L.
    Golub, Todd R.
    Getz, Gad
    Mills, Gordon B.
    Garraway, Levi A.
    Grandis, Jennifer R.
    [J]. JAMA ONCOLOGY, 2015, 1 (02) : 238 - 244
  • [9] Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma
    Hanna, Glenn J.
    Oakley, Liam B.
    Shi, Ruichao
    ONeill, Anne
    Shin, Kee-Young
    Sehgal, Kartik
    Dennis, Michael J.
    Jo, Vickie Y.
    Wong, Kristine S.
    Haddad, Robert I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis
    Chen, Long
    Mo, Dun-Chang
    Hu, Min
    Zhao, Shi-Jie
    Yang, Qiang-Wei
    Huang, Zhi-Ling
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2022, 43 (02)
12345